![]() | ||||
Le bulletin du Programme National de Mentorat sur le VIH-Sida et du volet Hépatites | ||||
Numéro 69, juin 2011 | ||||
Actualités | ||||
7e Symposium de Québec sur les aspects cliniques de l’infection par le VIH Travail social et VIH/sida 2011 : état des lieux et perspectives Essai HPTN-052: les antirétroviraux protègent contre l’infection du VIH Le PNMVS dans les médias sociaux! | ||||
Articles scientifiques | ||||
Thérapie antirétrovirale Risk of Triple-Class Virological Failure in Children with HIV: a Retrospective Cohort Study Toxicité et interactions médicamenteuses Cardiovascular Risks Associated with Abacavir and Tenofovir Exposure in HIV-Infected Person Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence Co-infections Treatment of Hepatitis C Virus (HCV) Infection in Patients Coinfected with HIV in the HIV Outpatient Study (HOPS), 1999–2007 Autres maladies associées Low CD4 Count is Associated with an Increased Risk of Fragility Fracture in HIV-infected Patients Risk of Heart Failure with Human Immunodeficiency Virus in the Absence of Prior Diagnosis of Coronary Heart Disease Vitamin D and Clinical Disease Progression in HIV Infection: Results from the EuroSIDA Study Hépatites Can Antiviral Therapy for Hepatitis C Reduce the Prevalence of HCV among Injecting Drug User Populations? A Modeling Analysis of its Prevention Utility Hepatitis C Virus Infection among Adolescents and Young Adults - Massachusetts, 2002-2009 Screen for HCV Based on Age, Not Risk Factors Communiqués de presse FDA approves Incivek for hepatitis C FDA approves new HIV treatment FDA approves Victrelis for Hepatitis C
| ||||
Communiquer avec nous | ||||
Pour toutes questions concernant le membership, les événements et les activités du PNMVS contacter: | ||||
© 2011 PNMVS |